EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy of homoharringtonine (HHT)-based induction regimen in acute myeloid leukemia (AML) with double-mutated CCAAT/enhancer-binding protein alpha (CEBPA): A prospective multicenter, single-arm phase II trial

Yan Hui, Fei Li, Benfa Gong, Yehui Tan, Zhongxing Jiang, Lin Yang, Xudong Wei, Yunliang Hao, Ling Qi, Sujun Gao, Haizhou Xing, Jianmin Luo und 4 weitere

Cancer Pathogenesis and Therapy · 2026-11 · 4 (6) · 498-506

DOI: 10.1016/j.cpt.2026.07.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Pathogenesis and Therapy, 2026-11. Verfasst von Yan Hui und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Homoharringtonine (HHT) suppresses the expression of the CCAAT/enhancer-binding protein alpha (CEBPA). Our previous retrospective analysis indicated that favorable outcomes were observed in acute myeloid leukemia (AML) with double-mutated CEBPA (CEBPAdm) when patients received an HHT-based induction regimen. To confirm these observations, we performed a prospective multicenter, single-arm trial to assess the efficacy of homoharringtonine, daunorubicin, and cytarabine (HAD) induction regimen in patients with CEBPAdm AML.

Methods

This prospective multicenter single-arm trial enrolled patients with newly diagnosed CEBPAdm AML who received the HAD induction regimen between June 1, 2020, and October 1, 2023. Consolidation therapy comprised three cycles of high-dose cytarabine (HDAC). The primary outcomes were event-free survival (EFS) and relapse-free survival (RFS). Secondary endpoints included complete remission (CR) rate, 30-day mortality, and overall survival (OS). Survival outcomes were estimated using the Kaplan-Meier method and compared with the log-rank test.

Results

A total of 61 patients with newly diagnosed CEBPAdm AML (median age 40 years, interquartile range [IQR] 30-47 years) were enrolled. After one course of HAD induction, 57 patients (93.44%) achieved CR, and the overall CR rate after one or two courses reached 95.08% (58/61). Among the 58 responders, 46 patients (79.31% [46/58]) achieved measurable residual disease (MRD) negativity after the first induction. The 30-day mortality rate was 3.28% (2/61). At a median follow-up of 31.97 months (IQR 21.27-37.77), the estimated 3-year EFS, RFS, and OS rates were 77.86%, 82.16%, and 87.27%, respectively. Exploratory subgroup analyses showed a numerical trend toward inferior RFS in patients with the co-occurring colony stimulating factor 3 receptor (CSF3R)T618I mutation (P = 0.064); however, given the small subgroup size, these findings are hypothesis-generating only and require validation in larger cohorts.

Conclusions

The HAD regimen demonstrated promising clinical activity and an acceptable safety profile in young adult patients with CEBPAdm AML, with 3-year EFS and RFS rates that met the predetermined objectives of 72% and 75%, respectively.

Trial registration

No. NCT04415008; https://classic.clinicaltrials.gov.

Schlagwörter

Stichwörter der Autor:innen

Acute myeloid leukemiaHomoharringtonineInduction chemotherapyTreatment outcome

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
  • Tianjin Institutes of Health Science, Tianjin 301600, China.
  • Jiangxi Provincial Key Laboratory of Hematological Diseases, Department of Hematology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330000, China.
  • Hematology Department, First Hospital of Jilin University, Changchun, Jilin 130021, China.
  • Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.
  • Department of Hematology, Key Laboratory of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.

Förderung

  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Hui, Y., Li, F., Gong, B., Tan, Y., Jiang, Z., Yang, L., Wei, X., Hao, Y., Qi, L., Gao, S., Xing, H., Luo, J., Zhao, Y., Liu, Q., Wang, J., & Wei, H. (2026). Efficacy of homoharringtonine (HHT)-based induction regimen in acute myeloid leukemia (AML) with double-mutated CCAAT/enhancer-binding protein alpha (CEBPA): A prospective multicenter, single-arm phase II trial. Cancer Pathogenesis and Therapy, 4(6), 498-506. https://doi.org/10.1016/j.cpt.2026.07.002

Vancouver

Hui Y, Li F, Gong B, Tan Y, Jiang Z, Yang L, et al. Efficacy of homoharringtonine (HHT)-based induction regimen in acute myeloid leukemia (AML) with double-mutated CCAAT/enhancer-binding protein alpha (CEBPA): A prospective multicenter, single-arm phase II trial. Cancer Pathogenesis and Therapy. 2026;4(6):498-506. doi:10.1016/j.cpt.2026.07.002

BibTeX
@article{Hui2026,
  author = {Hui, Yan and Li, Fei and Gong, Benfa and Tan, Yehui and Jiang, Zhongxing and Yang, Lin and Wei, Xudong and Hao, Yunliang and Qi, Ling and Gao, Sujun and Xing, Haizhou and Luo, Jianmin and Zhao, Yingsuo and Liu, Qianwei and Wang, Jianxiang and Wei, Hui},
  title = {Efficacy of homoharringtonine (HHT)-based induction regimen in acute myeloid leukemia (AML) with double-mutated CCAAT/enhancer-binding protein alpha (CEBPA): A prospective multicenter, single-arm phase II trial},
  journal = {Cancer Pathogenesis and Therapy},
  year = {2026},
  volume = {4},
  number = {6},
  pages = {498--506},
  doi = {10.1016/j.cpt.2026.07.002}
}
Kostenlos starten →